Thrombectomy Linked to Better Outcomes for Acute Stroke, Large Infarct

Better functional outcomes and lower mortality seen for thrombectomy plus medical care versus medical care alone
Thrombectomy Linked to Better Outcomes for Acute Stroke, Large Infarct
Adobe Stock
Medically Reviewed By:
Mark Arredondo, M.D.

THURSDAY, May 9, 2024 (HealthDay News) -- For patients with acute stroke and a large infarct, thrombectomy plus medical care results in better functional outcomes and lower mortality, according to a study published in the May 9 issue of the New England Journal of Medicine.

Vincent Costalat, M.D., Ph.D., from the Hôpital Gui de Chauliac, Montpellier in France, and colleagues assigned patients with proximal cerebral vessel occlusion in the anterior circulation and a large infarct detected on magnetic resonance imaging or computed tomography within 6.5 hours after symptom onset to undergo endovascular thrombectomy and receive medical care (thrombectomy group; 166 patients) or to receive medical care alone (control group; 167 patients).

Due to results of similar trials favoring thrombectomy, the trial was stopped early. The researchers found that about 35 percent of the patients received thrombolysis therapy. The median modified Rankin scale score at 90 days was 4 and 6 in the thrombectomy and control groups, respectively (generalized odds ratio, 1.63; 95 percent confidence interval, 1.29 to 2.06). At 90 days, death from any cause occurred in 36.1 and 55.5 percent of patients in the thrombectomy and control groups, respectively (adjusted relative risk, 0.65; 95 percent confidence interval, 0.50 to 0.84); the percentage of patients with symptomatic intracerebral hemorrhage was 9.6 and 5.7 percent, respectively (adjusted relative risk, 1.73; 95 percent confidence interval, 0.78 to 4.68).

"The use of thrombectomy plus medical care within seven hours after symptom onset led to a lower score on the modified Rankin scale at 90 days after randomization than medical care alone," the authors write.

The study was supported by Montpellier University Hospital through an unrestricted grant from an industry consortium of medical device companies (Medtronic, Stryker, Balt Extrusion, MicroVention, and Cerenovus).

Abstract/Full Text (subscription or payment may be required)

Related Stories

No stories found.